CJR-X (Comprehensive Care for Joint Replacement Expanded) Model — Proposed

Analysis updated November 9, 2026

Strategic questions for your team

What is our hospital's current LEJR episode volume relative to the 31-episode low-volume threshold, and across which MS-DRGs (469, 470, 521, 522) and HCPCS codes (27130, 27447) does that volume fall — because hospitals below 31 episodes in the applicable 3-year baseline period are excluded from reconciliation for that performance year, meaning we forgo both upside gain and downside repayment accountability?
Given that CJR-X applies a mandatory 2% discount factor to all episode spending (reducible to 1% for 'Good' CQS ≥12.1 and 0% for 'Excellent' CQS ≥17.1), and that the OACT Certification Memo estimates the target pricing methodology alone produces 0.6% net savings to Medicare before behavioral effects, what is our projected annual financial exposure or gain based on our current LEJR episode spending patterns, and do we have the care coordination infrastructure to outperform our regional benchmark?
Where do we currently score on each of the five quality measures comprising the Composite Quality Score — RSCR Following Elective Primary THA/TKA (CMIT #350, 50% domain weight), Hospital Visits Within 7 Days of HOPD Surgery (CMIT #344, weighted within complications domain), HCAHPS (CMIT #338, 40% patient experience domain weight), OAS CAHPS (CMIT #162), and THA/TKA PRO-PM (CMIT #1618, 10% domain weight) — and are we at risk of falling below the 6.0 CQS threshold that renders us ineligible for any reconciliation payment regardless of episode spending performance?
Are we currently participating in TEAM, and if so, when does our TEAM participation end (the model runs 2026–2030), because TEAM exclusion from CJR-X applies to both mandatory and voluntary TEAM participants and prevents concurrent participation — meaning our LEJR episode financial accountability structure will shift from a 30-day to a 90-day post-discharge window upon TEAM conclusion, fundamentally changing our post-acute cost exposure?
Do we qualify for the 5% stop-loss protection (versus the standard 20% stop-gain/stop-loss limits) available to hospitals with a high proportion of dually eligible Medicare-Medicaid patients, geographically rural hospitals, Medicare-dependent small rural hospitals, and Sole Community Hospitals — and given that the OACT memo estimates the 5% stop-loss reduces projected savings from 0.9% to 0.6% of episode spending, how does our specific stop-loss tier affect our maximum annual repayment exposure across our projected LEJR episode volume?
What is our current post-acute care utilization pattern — specifically our IRF discharge rate, SNF utilization rate, and home health spending — given that CJR evaluation data shows the original model achieved 3.4% episode spending reductions primarily through reduced IRF utilization, and that the OACT memo notes 86% of knee procedures and 61% of hip procedures are now performed in outpatient or ASC settings in 2024, raising the question of whether our remaining inpatient LEJR cases represent a higher-acuity, harder-to-manage population with limited remaining PAC optimization opportunity?
Have we confirmed our status on the CMS-released CJR-X Participant List, and do we have a clear understanding of which of our facilities are designated mandatory participants — because the participant list release means our obligation is now fixed and our 2027 preparation window is the primary lever for performance year outcomes starting January 1, 2028?
Given that CJR-X has no defined end date (unlike the original CJR model's fixed term), have we assessed the long-term capital and operational investment implications of building care coordination infrastructure that must sustain performance indefinitely, and does our governance structure reflect a permanent program rather than a time-limited pilot?
Have we executed the required CJR-X data sharing agreement (DSA) and data request and attestation (DRA) form — both submitted annually — to receive the beneficiary-identifiable claims data (summary and raw) and regional aggregate data that CMS will share monthly during performance years and for the 3-year baseline period, and do we have the analytics infrastructure to act on this data to manage episode costs against our regional benchmark pricing?
Which AAPM option (AAPM with CEHRT attestation and annual EHR Certification ID submission, or non-AAPM) will we elect for each performance year beginning January 1, 2028, and have we assessed whether our clinical collaborators — physician group practices, SNFs, home health agencies, and therapy providers — are prepared to meet the quarterly Financial Arrangements List and Clinician Engagement List reporting requirements that apply under the AAPM track?
Have we identified and executed written financial arrangement agreements with our key CJR-X collaborators (ACOs, physician group practices, SNFs, home health agencies) to enable gainsharing of reconciliation payments and alignment payments under the Anti-Kickback Statute Safe Harbor, and are we prepared to utilize the available Medicare program waivers — including up to 9 post-discharge home visits, telehealth geographic restriction waivers, and the SNF 3-day rule waiver (requiring SNF partners to hold a minimum 3-star CMS Five-Star rating for 7 of the past 12 months) — as care coordination tools to reduce 90-day episode spending?
Have we mapped our current hospital discharge process — including care transition protocols, post-discharge follow-up workflows, and patient navigation capabilities — specifically against the 90-day CJR-X accountability window, recognizing that discharge planning quality will be a primary determinant of episode cost performance and that weaknesses in this process represent direct financial exposure under a mandatory model?
Have we developed a population health strategy that spans the full 90-day episode — including pre-surgical optimization, inpatient care standardization, and post-acute network management — rather than relying solely on inpatient cost controls, given that expert commentary confirms a comprehensive population health approach is essential to CJR-X success and that hospitals without such infrastructure are at heightened financial risk?
Have we submitted the CJR-X Primary Point of Contact Identification Form for our hospital as listed on the CJR-X Participant List, and do we have an internal governance structure — including CFO, CMO, care coordination leadership, and legal/compliance representation — with accountability assigned for the January 1, 2028 model start date, the quarterly AAPM reporting cadences, annual DSA/DRA submissions, pre-discharge beneficiary notification requirements, and the collaborator list disclosure obligations?
Have we benchmarked our CJR-X readiness against peer institutions that are already standing up dedicated task forces and building operating capabilities in 2026–2027, and do we have a structured implementation timeline that ensures our care coordination infrastructure, collaborator agreements, data analytics, and quality improvement programs are operational well before January 1, 2028 — recognizing that the 2027 preparation window is the primary determinant of first-year performance?

Traps and concerns

Quality Gate Blocks Reconciliation Payment
CJR-X enforces a hard 'quality first' principle: hospitals with a Composite Quality Score (CQS) of 6.0 or below receive zero reconciliation payment regardless of how much they underspent their target price. The CQS is a weighted composite of five measures — Complications (50% weight), Patient Experience (40%), and PRO-PM (10%) — scored by national performance percentile. Any hospital falling below the 30th percentile on the two highest-weighted domains automatically scores 0 points on those measures, making a CQS above 6.0 structurally difficult. The OACT memo assumes 20% of hospitals will land in 'Below Acceptable' — meaning roughly one in five participating hospitals could do everything right on cost containment and still receive no upside payment. Critically, this quality floor does NOT relieve repayment obligations: a below-acceptable hospital that overspends its target still owes money to CMS. Hospitals operating near the quality threshold face an asymmetric risk: full downside exposure with zero upside capture.
Stop-Loss Asymmetry Traps High-Dual and Rural Hospitals
The 5% stop-loss protection for high-dual, geographically rural, Medicare-dependent small rural, and Sole Community Hospitals sounds protective but creates a structural trap. The OACT memo explicitly quantifies the cost: applying the 5% stop-loss (versus the standard 20%) reduces projected program savings from 0.9% to 0.6% of episode spending — a 0.3 percentage point reduction absorbed by CMS. From the hospital's perspective, this means that in a bad performance year, a qualifying rural or high-dual hospital's maximum repayment exposure is capped at 5% of cumulative target price versus 20% for peers. However, these same hospitals face greater clinical complexity (dual-eligibles are explicitly risk-adjusted using one of the 29 HCC adjusters, but imperfect risk adjustment remains a residual hazard), lower procedure volumes that may push them near the 31-episode low-volume threshold, and thinner administrative infrastructure to manage care coordination across the full 90-day window. If a rural hospital's annual LEJR volume falls below 31 episodes during the baseline period, they are excluded from reconciliation entirely for that performance year — meaning they bear all operational costs of participation with no payment upside, while their episodes still count toward future baselines.
Retrospective Trend Cap Creates Systematic Underpayment Risk
CJR-X uses a capped retrospective trend factor: the preliminary prospective trend applied to target prices can only be corrected at reconciliation by up to ±3% of the projected trend. If actual Medicare spending trends deviate from projections by more than 3% — a plausible scenario given post-pandemic utilization volatility and rapid site-of-service shifts from inpatient to outpatient and ASC — the target price will be systematically miscalibrated. The OACT memo acknowledges this risk, estimating that trend forecast errors alone could add 0.05 to 0.1 percentage points in reconciliation payments as a share of episode spending. The simplified payment example in the model overview illustrates the magnitude: a preliminary trend factor of 1.030 versus a reconciliation trend factor of 1.060 (a 3-point gap) already shifts the reconciliation target price from $94,241 to $95,863 — a $1,622 difference per episode. At scale across thousands of LEJR episodes per year, miscalibrated trend factors could mean hospitals are measured against targets that do not reflect actual market conditions, with no recourse if the error exceeds the 3% cap. Additionally, the normalization factor cap of 5% at reconciliation introduces a second compounding source of target price error that hospitals cannot predict at the start of a performance year.
Outpatient Episode Inclusion Creates Uncharted Attribution Complexity
CJR-X is the first mandatory episode model to include hospital outpatient LEJR procedures (HCPCS 27447 — Total Knee Arthroplasty and HCPCS 27130 — Total Hip Arthroplasty) alongside inpatient MS-DRGs. This creates novel attribution traps with no precedent from the original CJR model, which was inpatient-only. Specifically, the transfer rule states that if an outpatient LEJR is followed by an inpatient admission to the same CJR-X participant for the same episode type on the same day or within three days, the inpatient episode takes precedence — but the start date remains the outpatient procedure date. If the subsequent inpatient admission is to a different hospital, complex transfer attribution rules apply. Hospitals performing high outpatient volumes face accountability for 90 days of post-discharge spending on patients who may never return to their institution, have weaker care coordination relationships with community providers, and generate lower anchor payments (outpatient OPPS rates versus inpatient IPPS DRG rates) — compressing the financial headroom within the episode budget. By 2024, 86% of knee procedures and 61% of hip procedures were performed outside the inpatient setting, meaning the outpatient population now dominates episode volume, yet CJR-X's care coordination infrastructure and financial arrangements were designed around an inpatient model.
TEAM Exclusion Creates Participation Cliff and Successor Obligation
Hospitals currently participating in TEAM (which runs 2026–2030) are excluded from CJR-X. However, the exclusion ends when TEAM concludes or if a hospital no longer meets the TEAM participant definition — at which point those hospitals become mandatory CJR-X participants. This creates a 'participation cliff': TEAM hospitals will have invested years building 30-day episode management capabilities and will face an abrupt transition to a 90-day accountability window under CJR-X, requiring a fundamentally different post-acute care network, longer data monitoring infrastructure, and renegotiated collaborator financial arrangements. The model comparison slides make clear that CJR-X uses a different discount factor structure (quality-adjusted, 0–2%) versus TEAM's approach, and adds two outpatient quality measures (OAS CAHPS, Hospital Visits Within 7 Days of HOPD Surgery) that TEAM participants may not have been managing. Operationally, TEAM hospitals will have no transition period or 'voluntary' on-ramp to CJR-X — mandatory participation begins immediately upon TEAM exit. Any hospital that exits TEAM early (e.g., due to low volume, termination, or structural change) faces the same immediate CJR-X obligation, potentially mid-year, with no baseline data or preliminary target prices calibrated for their episode mix.
PRO-PM Data Collection Requirement Is Now Mandatory
Unlike the original CJR model — where Patient-Reported Outcome submission was voluntary — CJR-X requires the Hospital-Level THA/TKA PRO-PM (CMIT ID #1618) as one of five mandatory quality measures carrying 10% of the Composite Quality Score. This measure applies to both inpatient and outpatient episodes. Hospitals that did not build PRO collection workflows under CJR will need to implement patient-facing data collection systems, integrate results into EHR workflows, and ensure submission to the Hospital Inpatient Quality Reporting (HIQR) and Hospital Outpatient Quality Reporting (HOQR) programs — all before January 1, 2028. Hospitals that underperform on PRO-PM and fall below the 30th percentile receive 0 points on this domain. While 10% weight appears modest, combined with weak performance on complications or patient experience, it can be the marginal difference between an 'Acceptable' CQS (discount factor 2.0%, eligible for payment) and 'Good' (discount factor 1.0%). On a $95,863 reconciliation target price from the model's own example, the difference between a 1% and 2% discount factor is approximately $959 per episode — multiplied across a hospital's full episode volume, this is a material annual financial swing driven entirely by PRO collection infrastructure readiness.
Financial Arrangement Compliance Requires Quarterly Reporting Infrastructure
CJR-X participants electing the Advanced APM (AAPM) option must submit Financial Arrangement Lists and Clinician Engagement Lists quarterly for every performance year. Each list must include the name, Tax Identification Number (TIN), and National Provider Identifier (NPI) for every physician, nonphysician practitioner, or therapist who is either in a financial arrangement with the participant or has a contractual relationship and participates in CJR-X activities — along with start and end dates. Failure to submit, or submission of inaccurate data, creates compliance exposure under the Anti-Kickback Statute safe harbor, which is the legal foundation for all gainsharing arrangements between the participant hospital, collaborators (e.g., ACOs), collaboration agents (e.g., physician group practices), and downstream collaboration agents (e.g., individual physicians). The safe harbor explicitly permits sharing of reconciliation payments and repayment alignment — but only within properly documented financial arrangements. Hospitals with large, fluid medical staff communities — particularly those managing seasonal or locum clinician relationships — face significant ongoing administrative burden to maintain accurate quarterly rosters. Additionally, technology incentives to beneficiaries (e.g., home monitoring devices) valued over $75 must remain hospital property and be retrieved at episode end or documented as good-faith retrieval attempts, creating a physical asset management obligation that most hospital compliance programs have no existing process to execute.